{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:19Z","timestamp":1786987039385,"version":"build-2736575974"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1016\/j.coi.2020.04.005","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T11:56:00Z","timestamp":1590839760000},"page":"88-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma"],"prefix":"10.1016","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2615-8338","authenticated-orcid":false,"given":"Steven E","family":"Mutsaers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1571-2532","authenticated-orcid":false,"given":"Fiona J","family":"Pixley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-263X","authenticated-orcid":false,"given":"Cecilia M","family":"Pr\u00eale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7370-9139","authenticated-orcid":false,"given":"Gerard F","family":"Hoyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2020.04.005_bib0005","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2016.09.005","article-title":"Mesothelial cells and peritoneal homeostasis","volume":"106","author":"Mutsaers","year":"2016","journal-title":"Fertil Steril"},{"key":"10.1016\/j.coi.2020.04.005_bib0010","series-title":"Textbook of Pleural Diseases","article-title":"Mesothelial cells and pleural immunology","author":"Mutsaers","year":"2016"},{"key":"10.1016\/j.coi.2020.04.005_bib0015","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.resp.2010.12.012","article-title":"Tight junction proteins contribute to barrier properties in human pleura","volume":"175","author":"Markov","year":"2011","journal-title":"Respir Physiol Neurobiol"},{"key":"10.1016\/j.coi.2020.04.005_bib0020","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.tice.2016.11.004","article-title":"The histophysiology and pathophysiology of the peritoneum","volume":"49","author":"van Baal","year":"2017","journal-title":"Tissue Cell"},{"key":"10.1016\/j.coi.2020.04.005_bib0025","doi-asserted-by":"crossref","first-page":"L461","DOI":"10.1152\/ajplung.00276.2007","article-title":"Innate immune responses in murine pleural mesothelial cells: toll-like receptor-2 dependent induction of beta-defensin-2 by staphylococcal peptidoglycan","volume":"295","author":"Hussain","year":"2008","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"10.1016\/j.coi.2020.04.005_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0031710","article-title":"Differentiation and recruitment of Th9 cells stimulated by pleural mesothelial cells in human Mycobacterium tuberculosis infection","volume":"7","author":"Ye","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.coi.2020.04.005_bib0035","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201107-1198OC","article-title":"Differentiation and recruitment of IL-22-producing helper T cells stimulated by pleural mesothelial cells in tuberculous pleurisy","volume":"185","author":"Ye","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0040","doi-asserted-by":"crossref","first-page":"6456","DOI":"10.18632\/oncotarget.27290","article-title":"Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications","volume":"10","author":"Donnenberg","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.coi.2020.04.005_bib0045","doi-asserted-by":"crossref","first-page":"6301","DOI":"10.1038\/onc.2010.437","article-title":"Harnessing the immune response to treat cancer","volume":"29","author":"Steer","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.coi.2020.04.005_bib0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/s41571-019-0291-4","article-title":"Immunotherapy trials in mesothelioma - promising results, but don\u2019t stop here","volume":"16","author":"Nowak","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/5804230","article-title":"Complex immune contextures characterise malignant peritoneal mesothelioma: loss of adaptive immunological signature in the more aggressive histological types","volume":"2018","author":"Tazzari","year":"2018","journal-title":"J Immunol Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0060","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/1753465816628800","article-title":"Malignant pleural mesothelioma: an update on diagnosis and treatment options","volume":"10","author":"Kondola","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.coi.2020.04.005_bib0065","doi-asserted-by":"crossref","DOI":"10.1186\/s13104-018-3953-x","article-title":"Tumour associated lymphocytes in the pleural effusions of patients with mesothelioma express high levels of inhibitory receptors","volume":"11","author":"Chee","year":"2018","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.coi.2020.04.005_bib0070","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1638211","article-title":"Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes","volume":"8","author":"Klampatsa","year":"2019","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2020.04.005_bib0075","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2018.00526","article-title":"Macrophage depletion in elderly mice improves response to tumor immunotherapy, increases anti-tumor T cell activity and reduces treatment-induced cachexia","volume":"9","author":"Duong","year":"2018","journal-title":"Front Genet"},{"key":"10.1016\/j.coi.2020.04.005_bib0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/ijc.2910510220","article-title":"Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature","volume":"51","author":"Schmitter","year":"1992","journal-title":"Int J Cancer"},{"key":"10.1016\/j.coi.2020.04.005_bib0085","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1038\/ni.1937","article-title":"Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm","volume":"11","author":"Biswas","year":"2010","journal-title":"Nat Immunol"},{"key":"10.1016\/j.coi.2020.04.005_bib0090","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.arr.2017.03.008","article-title":"Aging and cancer: the role of macrophages and neutrophils","volume":"36","author":"Jackaman","year":"2017","journal-title":"Ageing Res Rev"},{"key":"10.1016\/j.coi.2020.04.005_bib0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2014.00587","article-title":"Depletion of tumor-associated macrophages slows the growth of chemically induced mouse lung adenocarcinomas","volume":"5","author":"Fritz","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.coi.2020.04.005_bib0100","article-title":"High infiltration of tumor-associated macrophages influences poor prognosis in human gastric cancer patients, associates with the phenomenon of EMT","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.coi.2020.04.005_bib0105","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1002\/cncr.26143","article-title":"Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma","volume":"117","author":"Burt","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.coi.2020.04.005_bib0110","article-title":"Prognostic and predictive aspects of the tumor immune microenvironment and immune checkpoints in malignant pleural mesothelioma","volume":"6","author":"Marcq","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2020.04.005_bib0115","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1009285","article-title":"The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers","volume":"4","author":"Ujiie","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2020.04.005_bib0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12307-012-0100-4","article-title":"The role of regulatory T cells in mesothelioma","volume":"5","author":"Ireland","year":"2012","journal-title":"Cancer Microenviron"},{"key":"10.1016\/j.coi.2020.04.005_bib0125","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0130","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1084\/jem.20150204","article-title":"A novel IL-17 signaling pathway controlling keratinocyte proliferation and tumorigenesis via the TRAF4-ERK5 axis","volume":"212","author":"Wu","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.coi.2020.04.005_sbref0135","doi-asserted-by":"crossref","first-page":"4575","DOI":"10.1073\/pnas.1820388116","article-title":"Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity","volume":"116","author":"Onda","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.04.005_bib0140","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.celrep.2017.06.062","article-title":"Crosstalk between regulatory T cells and tumor-associated dendritic cells negates anti-tumor immunity in pancreatic cancer","volume":"20","author":"Jang","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.coi.2020.04.005_bib0145","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.immuni.2015.08.006","article-title":"Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses","volume":"43","author":"Joshi","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.coi.2020.04.005_bib0150","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0155","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S1470-2045(17)30169-9","article-title":"Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial","volume":"18","author":"Alley","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coi.2020.04.005_sbref0160","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(18)30420-X","article-title":"Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial","volume":"7","author":"Disselhorst","year":"2019","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0165","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1158\/1078-0432.CCR-19-0103","article-title":"Clinical efficacy and safety of nivolumab: results of a multicenter, open-label, single-arm, Japanese phase II study in malignant pleural mesothelioma (MERIT)","volume":"25","author":"Okada","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0170","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","article-title":"Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential","volume":"161","author":"Sharma","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.coi.2020.04.005_bib0175","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1186\/s13063-018-2602-y","article-title":"CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial","volume":"19","author":"Fennell","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.coi.2020.04.005_bib0180","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdz394.091","article-title":"A multicentre randomized phase III trial comparing pembrolizumab (P) vs single agent chemotherapy (CT) for advanced pre-treated malignant pleural mesothelioma (MPM): Results from the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial","volume":"30","author":"Popat","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0185","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2018.5428","article-title":"Efficacy and safety of avelumab treatment in patients with advanced unresectable mesothelioma: phase 1b results from the JAVELIN solid tumor trial","volume":"5","author":"Hassan","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0190","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/S1470-2045(13)70381-4","article-title":"Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial","volume":"14","author":"Calabr\u00f2","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0195","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0200","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/s41379-019-0364-z","article-title":"V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma","volume":"33","author":"Muller","year":"2020","journal-title":"Mod Pathol"},{"key":"10.1016\/j.coi.2020.04.005_sbref0205","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay0524","article-title":"VISTA is a checkpoint regulator for na\u00efve T cell quiescence and peripheral tolerance","volume":"367","author":"ElTanbouly","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.coi.2020.04.005_sbref0210","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1494111","article-title":"Combination immune checkpoint blockade as an effective therapy for mesothelioma","volume":"7","author":"Fear","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.coi.2020.04.005_bib0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0220","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2159-8290.CD-15-0583","article-title":"Mesothelin-targeted CARs: driving T cells to solid tumors","volume":"6","author":"Morello","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.coi.2020.04.005_sbref0230","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.ccell.2015.09.004","article-title":"Structural design of engineered costimulation determines tumor rejection kinetics and persistence of CAR T cells","volume":"28","author":"Zhao","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.coi.2020.04.005_bib0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0240","first-page":"181","article-title":"Characterization of the antigen (CAK1) recognized by monoclonal antibody K1 present on ovarian cancers and normal mesothelium","volume":"52","author":"Chang","year":"1992","journal-title":"Cancer Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0245","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-213X-3-2","article-title":"Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells","volume":"3","author":"Prieve","year":"2003","journal-title":"BMC Dev Biol"},{"key":"10.1016\/j.coi.2020.04.005_bib0250","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.bbrc.2013.09.025","article-title":"Expression profile and function of Wnt signaling mechanisms in malignant mesothelioma cells","volume":"440","author":"Fox","year":"2013","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.coi.2020.04.005_bib0255","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s12079-017-0411-9","article-title":"Sulfatase-1 knockdown promotes in vitro and in vivo aggressive behavior of murine hepatocarcinoma Hca-P cells through up-regulation of mesothelin","volume":"12","author":"Mahmoud","year":"2018","journal-title":"J Cell Commun Signal"},{"key":"10.1016\/j.coi.2020.04.005_sbref0260","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3010162","article-title":"Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity","volume":"6","author":"Adusumilli","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2020.04.005_bib0265","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.coi.2020.04.005_bib0270","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13046-020-01546-6","article-title":"Genetic and pharmacological targeting of A2a receptor improves function of anti-mesothelin CAR T cells","volume":"39","author":"Masoumi","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0275","doi-asserted-by":"crossref","first-page":"9190","DOI":"10.1074\/jbc.M312372200","article-title":"Binding of ovarian cancer antigen CA125\/MUC16 to mesothelin mediates cell adhesion","volume":"279","author":"Rump","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.coi.2020.04.005_bib0280","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"10.1016\/j.coi.2020.04.005_bib0285","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1158\/1541-7786.MCR-07-0254","article-title":"Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signal-regulated kinase signaling pathway in human breast cancer cells","volume":"6","author":"Uehara","year":"2008","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0290","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1042\/BJ20110282","article-title":"Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK\/ERK and JNK pathways","volume":"442","author":"Chang","year":"2012","journal-title":"Biochem J"},{"key":"10.1016\/j.coi.2020.04.005_bib0295","article-title":"Mesothelin binding to CA125\/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation","volume":"3","author":"Chen","year":"2013","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2020.04.005_bib0300","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0305","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1093\/carcin\/bgr075","article-title":"Mesothelin overexpression promotes autocrine IL-6\/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation","volume":"32","author":"Bharadwaj","year":"2011","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.coi.2020.04.005_bib0310","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-10-106","article-title":"Mesothelin confers pancreatic cancer cell resistance to TNF-\u03b1-induced apoptosis through Akt\/PI3K\/NF-\u03baB activation and IL-6\/Mcl-1 overexpression","volume":"10","author":"Bharadwaj","year":"2011","journal-title":"Mol Cancer"},{"key":"10.1016\/j.coi.2020.04.005_bib0315","doi-asserted-by":"crossref","first-page":"13832","DOI":"10.1073\/pnas.0406035101","article-title":"Listeria-based cancer vaccines that segregate immunogenicity from toxicity","volume":"101","author":"Brockstedt","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.04.005_bib0320","doi-asserted-by":"crossref","first-page":"5787","DOI":"10.1158\/1078-0432.CCR-19-0070","article-title":"Clinical response of live-attenuated, Listeria monocytogenes expressing mesothelin (CRS-207) with chemotherapy in patients with malignant pleural mesothelioma","volume":"25","author":"Hassan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.coi.2020.04.005_bib0325","article-title":"A pivotal randomized phase II study of anetumab ravtansine or vinorelbine in patients with advanced or metastatic pleural mesothelioma after progression on platinum\/pemetrexed-based chemotherapy (NCT02610140)","volume":"34","author":"Hassan","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0330","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.02085","article-title":"First-in-human, multicenter, phase I dose-escalation and expansion study of anti-mesothelin antibody-drug conjugate anetumab ravtansine in advanced or metastatic solid tumors","author":"Hassan","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.coi.2020.04.005_bib0335","article-title":"BMS-986148, an anti-mesothelin antibody-drug conjugate (ADC), alone or in combination with nivolumab demonstrates clinical activity in patients with select advanced solid tumors","volume":"18","author":"Clarke","year":"2019","journal-title":"AACR Mol Cancer Ther"},{"key":"10.1016\/j.coi.2020.04.005_bib0340","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s10637-014-0196-0","article-title":"Phase I study of amatuximab, a novel monoclonal antibody to mesothelin, in Japanese patients with advanced solid tumors","volume":"33","author":"Fujisaka","year":"2015","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.coi.2020.04.005_bib0345","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1128\/MCB.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.coi.2020.04.005_bib0350","doi-asserted-by":"crossref","first-page":"11515","DOI":"10.1073\/pnas.201398198","article-title":"Blockade of the granzyme B\/perforin pathway through overexpression of the serine protease inhibitor PI-9\/SPI-6 constitutes a mechanism for immune escape by tumors","volume":"98","author":"Medema","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2020.04.005_bib0355","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1002\/pros.21486","article-title":"Inhibition of granzyme B by PI-9 protects prostate cancer cells from apoptosis","volume":"72","author":"Ray","year":"2012","journal-title":"Prostate"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791520300492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791520300492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:44:10Z","timestamp":1760604250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791520300492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":71,"alternative-id":["S0952791520300492"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2020.04.005","relation":{},"ISSN":["0952-7915"],"issn-type":[{"value":"0952-7915","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mesothelial cells regulate immune responses in health and disease: role for immunotherapy in malignant mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2020.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}